More than twenty years of study has provided a better understanding of hepatitis C virus
(HCV) life cycle, including the general properties of viral RNA and proteins. This effort …

Background Direct‐acting anti‐virals (DAAs) licensed to treat chronic HCV infection have
revolutionised treatment algorithms by drastically mitigating side effects while enhancing …

Human viral oncogenesis is a complex phenomenon and a major contributor to the global
cancer burden. Several recent findings revealed cellular and molecular pathways that …

Hepatitis C virus (HCV) infection is a major health problem worldwide. Approximately, 170-
200 million individuals are chronically infected worldwide and a quarter of these patients are …

New protein synthesis is known to be required for the consolidation of memories, yet existing
methods of blocking translation lack spatiotemporal precision and cell-type specificity …

Although interferon‐free antiviral treatment is expected to improve treatment of hepatitis C, it
is unclear to what extent pre‐existing drug‐resistant amino acid substitutions influence …

Hepatitis C virus (HCV) infection is a major worldwide health problem. Chronic infection
induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual …

The ongoing global pandemic of COVID-19 has brought life to almost a standstill with the
implementation of lockdowns and social distancing as some of the preventive measures in …

Hepatitis, a global public health concern, presents a significant burden on healthcare
systems worldwide. Particularly, hepatitis B and C are viral infections that can lead to severe …

Background: Advances in the development of Direct-Acting Antivirals (DAAs), particularly
pangenotypic drugs, have led to a high rate of hepatitis C virus (HCV) eradication. Notably …